Efficacy and adverse events related to the initial dose of methimazole in children and adolescents with Graves’ disease

PURPOSE: The first-line antithyroid drug for children and adolescents with Graves’ disease (GD) is methimazole (MMI). This study evaluated the relationship between the initial MMI dose and the clinical course of GD after treatment. METHODS: We studied the efficacy of the initial MMI dose and the rel...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Hyun Gyung, Yang, Eun Mi, Kim, Chan Jong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Pediatric Endocrinology 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505040/
https://www.ncbi.nlm.nih.gov/pubmed/34610704
http://dx.doi.org/10.6065/apem.2142046.023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505040/
https://www.ncbi.nlm.nih.gov/pubmed/34610704
http://dx.doi.org/10.6065/apem.2142046.023

Ejemplares similares